Yu‐Ching Wen

843 total citations
37 papers, 640 citations indexed

About

Yu‐Ching Wen is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Yu‐Ching Wen has authored 37 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 14 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Yu‐Ching Wen's work include Prostate Cancer Treatment and Research (9 papers), Renal and related cancers (4 papers) and Renal cell carcinoma treatment (3 papers). Yu‐Ching Wen is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Renal and related cancers (4 papers) and Renal cell carcinoma treatment (3 papers). Yu‐Ching Wen collaborates with scholars based in Taiwan, United States and Lebanon. Yu‐Ching Wen's co-authors include Ming‐Hsien Chien, Shun‐Fa Yang, Wei‐Jiunn Lee, Michael Hsiao, Jyh‐Ming Chow, Tsui‐Hwa Tseng, Liang-Ming Lee, Yung‐Wei Lin, Chiao‐Wen Lin and Wei-Jiunn Lee and has published in prestigious journals such as SHILAP Revista de lepidopterología, Oncogene and International Journal of Molecular Sciences.

In The Last Decade

Yu‐Ching Wen

35 papers receiving 632 citations

Peers

Yu‐Ching Wen
Hongyan Chai China
Neha Merchant India
Ayesha Rashid Canada
Sarmistha Banerjee United States
Ping Fang China
Weili Min China
Jasmin Shafarin United Arab Emirates
Noriko Kanaya United States
Yeon Ho Choi South Korea
Robert Kleszcz Poland
Hongyan Chai China
Yu‐Ching Wen
Citations per year, relative to Yu‐Ching Wen Yu‐Ching Wen (= 1×) peers Hongyan Chai

Countries citing papers authored by Yu‐Ching Wen

Since Specialization
Citations

This map shows the geographic impact of Yu‐Ching Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu‐Ching Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu‐Ching Wen more than expected).

Fields of papers citing papers by Yu‐Ching Wen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu‐Ching Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu‐Ching Wen. The network helps show where Yu‐Ching Wen may publish in the future.

Co-authorship network of co-authors of Yu‐Ching Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Yu‐Ching Wen. A scholar is included among the top collaborators of Yu‐Ching Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu‐Ching Wen. Yu‐Ching Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Su, Wen‐Lin, et al.. (2025). Assessing Traditional Chinese Medicines for Anti‐Dengue Using a National Health Insurance Research Database and Bioassays. Food Science & Nutrition. 13(3). e70009–e70009. 1 indexed citations
2.
Wen, Yu‐Ching, Yung‐Wei Lin, Kuo-Hao Ho, et al.. (2024). The oncogenic ADAMTS1–VCAN–EGFR cyclic axis drives anoikis resistance and invasion in renal cell carcinoma. Cellular & Molecular Biology Letters. 29(1). 126–126. 4 indexed citations
3.
Tung, Min‐Che, et al.. (2024). Associations of the Expression Levels and Risk Variants of CDKN2B‐AS1 Long Noncoding RNA With the Susceptibility and Progression of Prostate Cancer. Journal of Cellular and Molecular Medicine. 28(23). e70264–e70264. 1 indexed citations
4.
5.
Chen, Wei‐Yu, Hsiu‐Lien Yeh, Weihao Chen, et al.. (2023). Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer. Redox Biology. 62. 102686–102686. 14 indexed citations
6.
Yang, Yi‐Chieh, Yung‐Wei Lin, Wei‐Jiunn Lee, et al.. (2023). The RNA-binding protein KSRP aggravates malignant progression of clear cell renal cell carcinoma through transcriptional inhibition and post-transcriptional destabilization of the NEDD4L ubiquitin ligase. Journal of Biomedical Science. 30(1). 68–68. 10 indexed citations
7.
Wen, Yu‐Ching, Shian‐Shiang Wang, Yung‐Wei Lin, et al.. (2023). Genetic variants of dipeptidyl peptidase IV are linked to the clinicopathologic development of prostate cancer. Journal of Cellular and Molecular Medicine. 27(17). 2507–2516. 4 indexed citations
8.
Wen, Yu‐Ching, Chien‐Hsiu Li, Hsiu‐Lien Yeh, et al.. (2023). CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer. Cell Death and Disease. 14(5). 304–304. 9 indexed citations
9.
Wen, Yu‐Ching, et al.. (2023). Functional variants of the chitinase 3‐like 1 gene are associated with clinicopathologic outcomes and progression of prostate cancer. Journal of Cellular and Molecular Medicine. 27(24). 4202–4214. 4 indexed citations
10.
Wen, Yu‐Ching, Wei‐Yu Chen, Hsiu‐Lien Yeh, et al.. (2022). Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency. Cell Death and Disease. 13(3). 252–252. 12 indexed citations
11.
Tung, Min‐Che, Yung‐Wei Lin, Wei‐Jiunn Lee, et al.. (2022). Targeting DRD2 by the antipsychotic drug, penfluridol, retards growth of renal cell carcinoma via inducing stemness inhibition and autophagy-mediated apoptosis. Cell Death and Disease. 13(4). 400–400. 24 indexed citations
12.
Wen, Yu‐Ching, Chien‐Liang Liu, Hsiu‐Lien Yeh, et al.. (2021). PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer. British Journal of Cancer. 126(5). 778–790. 8 indexed citations
13.
Wen, Yu‐Ching, Yen‐Nien Liu, Hsiu‐Lien Yeh, et al.. (2021). TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer. Oncogenesis. 10(11). 81–81. 11 indexed citations
14.
Chiu, Shao‐Chih, Der‐Yang Cho, Liang‐Ming Lee, et al.. (2020). Gamma/Delta T-Cells Enhance Carboplatin-induced Cytotoxicity Towards Advanced Bladder Cancer Cells. Anticancer Research. 40(9). 5221–5227. 7 indexed citations
15.
Wang, Shih‐Wei, Yun‐Ru Chen, Jyh‐Ming Chow, et al.. (2018). Stimulation of Fas/FasL‐mediated apoptosis by luteolin through enhancement of histone H3 acetylation and c‐Jun activation in HL‐60 leukemia cells. Molecular Carcinogenesis. 57(7). 866–877. 28 indexed citations
16.
Chen, Wei‐Yu, Kuo‐Tai Hua, Wei-Jiunn Lee, et al.. (2016). Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy. International Journal of Molecular Sciences. 17(8). 1194–1194. 2 indexed citations
17.
Tseng, Tsui‐Hwa, Ming‐Hsien Chien, Wea‐Lung Lin, et al.. (2016). Inhibition of MDA‐MB‐231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation‐mediated p21WAF1/CIP1expression. Environmental Toxicology. 32(2). 434–444. 111 indexed citations
18.
Yao, Chih‐Jung, Yung-Wei Lin, Yu‐Ching Wen, et al.. (2013). Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling. Oncology Letters. 5(5). 1541–1545. 29 indexed citations
19.
Chien, Ming‐Hsien, Chiao‐Wen Lin, Chao‐Wen Cheng, Yu‐Ching Wen, & Shun‐Fa Yang. (2012). Matrix metalloproteinase-2 as a target for head and neck cancer therapy. Expert Opinion on Therapeutic Targets. 17(2). 203–216. 77 indexed citations
20.
Lin, Yung-Wei, et al.. (2012). Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia. The Aging Male. 15(4). 246–252. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hongyan Chai Breakdown of academic impact, for papers by Neha Merchant Breakdown of academic impact, for papers by Ayesha Rashid Breakdown of academic impact, for papers by Sarmistha Banerjee Breakdown of academic impact, for papers by Ping Fang Breakdown of academic impact, for papers by Weili Min Breakdown of academic impact, for papers by Jasmin Shafarin Breakdown of academic impact, for papers by Noriko Kanaya Breakdown of academic impact, for papers by Yeon Ho Choi Breakdown of academic impact, for papers by Robert Kleszcz
Rankless by CCL
2026